A new trading day began on Tuesday, with Spyre Therapeutics Inc (NASDAQ: SYRE) stock price up 3.49% from the previous day of trading, before settling in for the closing price of $22.90. SYRE’s price has ranged from $20.07 to $47.97 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -37.38%. Meanwhile, its annual earnings per share averaged 91.31%. With a float of $49.95 million, this company’s outstanding shares have now reached $51.40 million.
Let’s determine the extent of company efficiency that accounts for 30 employees. In terms of profitability, gross margin is 7.49%, operating margin of -18543.86%, and the pretax margin is -20619.19%.
Spyre Therapeutics Inc (SYRE) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Spyre Therapeutics Inc is 14.92%, while institutional ownership is 80.11%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.
Spyre Therapeutics Inc (SYRE) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 91.31% per share during the next fiscal year.
Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators
Here are Spyre Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 9.21, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -3.86 in one year’s time.
Technical Analysis of Spyre Therapeutics Inc (SYRE)
Looking closely at Spyre Therapeutics Inc (NASDAQ: SYRE), its last 5-days average volume was 0.66 million, which is a jump from its year-to-date volume of 0.59 million. As of the previous 9 days, the stock’s Stochastic %D was 85.18%. Additionally, its Average True Range was 1.52.
During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 17.24%, which indicates a significant decrease from 96.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.77% in the past 14 days, which was lower than the 59.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.20, while its 200-day Moving Average is $29.00. However, in the short run, Spyre Therapeutics Inc’s stock first resistance to watch stands at $24.16. Second resistance stands at $24.61. The third major resistance level sits at $25.39. If the price goes on to break the first support level at $22.92, it is likely to go to the next support level at $22.14. Should the price break the second support level, the third support level stands at $21.69.
Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats
With a market capitalization of 1.39 billion, the company has a total of 51,431K Shares Outstanding. Currently, annual sales are 890 K while annual income is -338,790 K. The company’s previous quarter sales were 0 K while its latest quarter income was -69,030 K.
